Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?

Med. 2024 May 10;5(5):380-382. doi: 10.1016/j.medj.2024.03.011.

Abstract

Wagenlehner and colleagues1 demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. A major area of interest in real-world application of cefepime/taniborbactam is its potential role in treating carbapenem-resistant infections, which deserves further investigation.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Borinic Acids
  • Carbapenems* / pharmacology
  • Carbapenems* / therapeutic use
  • Carboxylic Acids
  • Cefepime* / pharmacology
  • Cefepime* / therapeutic use
  • Cephalosporins / pharmacology
  • Cephalosporins / therapeutic use
  • Drug Combinations
  • Gram-Negative Bacterial Infections / drug therapy
  • Humans
  • Meropenem / pharmacology
  • Meropenem / therapeutic use
  • Pyelonephritis / drug therapy
  • Pyelonephritis / microbiology
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / microbiology

Substances

  • Cefepime
  • Anti-Bacterial Agents
  • Carbapenems
  • taniborbactam
  • Cephalosporins
  • Drug Combinations
  • Meropenem
  • Borinic Acids
  • Carboxylic Acids